|
Feb 18
|
|
$208.67
$208.67
-0.0%
|
LONG
|
Abby Abu Omar
Crypto reporter, CoinDesk
|
Berkshire Hathaway bought shares in The New York Times, AstraZeneca, and Occidental Petroleum. This represents a classic defensive rotation: Media (subscription stability), Healthcare (drug demand independent of economy), and Energy (inflation hedge). LONG NYT, AZN, OXY. Sector-specific regulatory risks (drug pricing for AZN, oil prices for OXY). |
Bloomberg Markets
Lagarde Reported to Leave ECB Before Term End...
|
|
Feb 18
|
|
$208.67
$208.67
-0.0%
|
SHORT
|
Benzinga
|
The article reports that AstraZeneca has an RSI of 89, which is deep into overbought territory (above 70). The stock has gained approximately 14% over the past month and is trading near its 52-week high. An extremely high RSI often indicates that buying pressure is exhausted and the asset is vulnerable to a mean-reversion or a price pullback. The article explicitly flags AZN as a stock that "may collapse." Based on the overextended technical indicator, a short position is proposed to capitalize on a potential short-term price correction as traders take profits. The underlying fundamental news is very strong (upbeat earnings, 16 blockbuster drugs, positive CEO commentary). This positive momentum could continue, causing the stock to ignore the overbought signal and trend higher. |
Finnhub - AZN
Top 3 Health Care Stocks That May Collapse Th...
|
|
Feb 18
|
|
$208.67
$208.67
-0.0%
|
LONG
|
Jim Lebenthal
|
Jim Lebenthal of Cerity Partners described AstraZeneca as a "high-quality pharmaceutical stock." The company recently reported Q4 2025 adjusted EPS of $2.12, beating the consensus of $2.09. The combination of a positive "quality" endorsement from a market professional and a recent fundamental proof point (an earnings beat) provides a solid foundation for investment. This suggests stability and defensive growth characteristics. A long position is justified based on demonstrated financial outperformance in a defensive sector, appealing to investors seeking quality and resilience. The earnings beat was marginal. The pharmaceutical sector is always subject to risks from clinical trial failures, patent expirations, and government pricing pressures. |
Finnhub - AAPL
Apple, Ulta Beauty, AstraZeneca And A Real Es...
|
|
Feb 18
|
|
$208.67
$208.67
-0.0%
|
LONG
|
Oliver Crook
Chief European Correspondent, Bloomberg
|
13F filings reveal Berkshire Hathaway has been "buying into AstraZeneca" while simultaneously slashing stakes in major US tech and financials. When the "Oracle of Omaha" rotates out of cyclical consumer/tech names into defensive healthcare, it signals a shift toward safety and undervaluation in the pharma sector. LONG AZN as a copy-trade of Berkshire's defensive rotation. Drug pipeline failures or regulatory pricing pressure in the pharmaceutical sector. |
Bloomberg Markets
US-Iran Talks 'Progress' & Lagarde Reported t...
|
|
Feb 17
|
|
$209.48
$208.67
-0.4%
|
N/A
|
Finnhub News
|
— |
Finnhub - AZN
Harbor International Compounders ETF Q4 2025 ...
|
|
Feb 13
|
|
$205.55
$208.67
+1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - AZN
Results From Phase III KALOS And LOGOS Trials...
|
|
Feb 12
|
|
$204.52
$208.67
+2.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - AZN
Big Deal, Bigger Doubts: CSPC Slides After $1...
|
|
Feb 12
|
|
$204.52
$208.67
+2.0%
|
LONG
|
Elfreda Jonker
Investment Specialist, Alphinity Investment Management
|
The market is panic-selling companies perceived as "AI Disruptable" (Software, Services). Investors should seek "Non-AI Risk Trades"—companies with hard assets or complex pipelines that AI cannot easily replicate. Caterpillar (Heavy Machinery) and AstraZeneca (Pharma Pipeline) represent physical/complex value that is safe from the "AI Scare" narrative. Buy high-quality "Real World" companies as a defensive play against the AI disruption narrative. Global economic slowdown hurting industrials (CAT) or drug trial failures (AZN). |
Bloomberg Markets
US House Defies Trump on Canada Tariffs | The...
|